Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Current Assets (2016 - 2025)

Historic Current Assets for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $639.5 million.

  • Amphastar Pharmaceuticals' Current Assets rose 1713.0% to $639.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $639.5 million, marking a year-over-year increase of 1713.0%. This contributed to the annual value of $534.1 million for FY2024, which is 908.31% up from last year.
  • Amphastar Pharmaceuticals' Current Assets amounted to $639.5 million in Q3 2025, which was up 1713.0% from $580.8 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Current Assets registered a high of $639.5 million during Q3 2025, and its lowest value of $300.2 million during Q1 2021.
  • Its 5-year average for Current Assets is $446.7 million, with a median of $407.7 million in 2023.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Current Assets surged by 4132.58% in 2023 and then soared by 54.22% in 2024.
  • Over the past 5 years, Amphastar Pharmaceuticals' Current Assets (Quarter) stood at $318.1 million in 2021, then rose by 18.92% to $378.3 million in 2022, then grew by 29.41% to $489.6 million in 2023, then rose by 9.08% to $534.1 million in 2024, then rose by 19.74% to $639.5 million in 2025.
  • Its last three reported values are $639.5 million in Q3 2025, $580.8 million for Q2 2025, and $588.0 million during Q1 2025.